View ValuationScopus BioPharma 将来の成長Future 基準チェック /06現在、 Scopus BioPharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 20Scopus BioPharma Files Form 15Scopus BioPharma Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Nov 08Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant GliomaScopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski, Professor of Immuno-Oncology at City of Hope, is the Co-Founder and Senior Scientific Advisor of Duet. Duet is developing novel immunotherapies to overcome treatment-resistant cancers. DUET-102 is a double-stranded antisense oligonucleotide ("ASO") STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma. Glioma is a common type of tumor originating in the glial cells of the brain. Approximately 20,000 patients are diagnosed in the United States annually, with such patients having a 5-year survival rate of less than 7%, reflecting the need for new therapies to combat this disease. The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete injection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice. DUET-102 creates ideal conditions for PD-1 blockade to recruit cancer-killing effector CD8 positive T cells into the tumor by activating intratumoral dendritic cells, M1 macrophages, and microglia, while concurrently reducing immunosuppressive tumor-associated M2 macrophages, resting microglia, and regulatory T cells. DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma. DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs. Furthermore, the effectiveness of DUET-102 in releasing immunosuppression may enhance the efficacy of other T-cell based immunotherapies in the context of glioma, including potential combinations of DUET-102 with adoptive cell transfer therapies, such as CAR T-cell therapies.お知らせ • Dec 17Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price RequirementAs previously disclosed, Scopus BioPharma Inc. has not satisfied certain requirements for continued listing of the Nasdaq Stock Market LLC (“Nasdaq”), including: (i) the minimum Market Value of Listed Securities; (ii) the minimum Market Value of Publicly Held Shares; and (iii) the minimum closing bid price. As also previously disclosed, the Company had a hearing, on August 25, 2022, with the Nasdaq Hearings Panel (the “Panel”) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the “Compliance Plan”). By letter dated September 13, 2022, Nasdaq informed the Company of the Panel’s decision directing that the Company’s listing be transferred to the Nasdaq Capital Market and that the Company’s common stock would continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan. As reported on December 2, 2022, the Company failed to comply with, among other things, milestone dates included in the Compliance Plan. In response to the Company informing the Panel of an inability to complete a specified financing transaction by a subsequent milestone date, the Panel informed the Company, by letter dated December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol SCPS". The Company has submitted an application for trading of its common stock on the OTCQB Venture Market (the OTCQB"). The OTCQB requires, among other things, that companies be current with and otherwise satisfy applicable reporting requirements. The Company intends to continue to comply with applicable reporting requirements under the Securities Exchange Act of 1934. There can be no assurance that the Company's application to trade on the OTCQB will be approved on a timely basis or at all or that the Company will be able to satisfy reporting and other applicable requirements.お知らせ • Dec 05Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price RequirementAs previously reported, Scopus BioPharma Inc. (the ‘company’) received deficiency notification letters from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (‘Nasdaq’ or the ‘Exchange’) indicating that the Company was not in compliance with Nasdaq’s ‘minimum bid price’ requirement, which requires that the bid price of the stock of listed companies be at least $1.00 per share (the ‘Minimum Bid Price Requirement’) and certain Nasdaq listing rules relating to maintaining a minimum market value of listed securities of $50,000,000 (the ‘MVLS Requirement’) and a minimum market value of publicly held shares of $15,000,000 (the ‘MVPHS Requirement’ and, together with the Minimum Bid Price Requirement and the MVLS Requirement, the ‘Listing Requirements’). Also, as previously disclosed, the Company participated in a hearing on August 25, 2022 with the Nasdaq Hearings Panel (the ‘Panel’) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the ‘Compliance Plan’). Also, as previously disclosed, on September 13, 2022, Nasdaq informed the Company of the Panel’s decision (the ‘Decision’) directing that the Company’s listing be transferred to the Nasdaq Capital Market, effective at the open of business on September 15, 2022, and the Company’s common stock will continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan in full by no later than January 9, 2023. The Company failed to comply with milestone dates set forth in the Compliance Plan and did not timely inform Nasdaq of such failure. By letter dated December 1, 2022, Nasdaq informed the Company that the Panel has determined to grant the Company a final extension to such milestone dates and publicly reprimanded the Company. Such public reprimand, pursuant to Listing Rule 5815(c)(1)(D), was issued to the Company for its failure to comply with Listing Rule 5250(a)(1), requiring it to notify Nasdaq of certain significant developments that led to its prior representations about its ability to satisfy the terms of the Decision and, therefore, the Exchange’s continued listing requirements being inaccurate. While the Company is continuing to use its best efforts to satisfy the Listing Requirements in full by no later than January 9, 2023, there can be no assurance that the Company will be able to do so as set forth in the Compliance Plan, as amended, or at all. Failure to do so would result in the delisting of the Company’s common stock from Nasdaq, which would likely have a material adverse effect on the trading and value of the Company’s common stock.お知らせ • Nov 16Scopus BioPharma Inc. announced delayed 10-Q filingOn 11/15/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Dave Buckel was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 10Scopus Biopharma Receives Additional Non-Compliance Letter from NasdaqScopus BioPharma Inc. announced that on October 4, 2022, the company received additional letter from Nasdaq as the company had not regained compliance with minimum bid price standard as of October 3, 2022.お知らせ • Sep 17Scopus BioPharma Provides Delisting UpdateAs previously disclosed on a Form 8-K filed on September 2, 2022, Scopus BioPharma Inc., on August 25, 2022, presented its plan (the Compliance Plan") for regaining compliance with continued listing standards of the Nasdaq Stock Market LLC (Nasdaq") to the Nasdaq Hearings Panel (the Panel"). By letter dated September 13, 2022, Nasdaq informed the Company of the Panel's decision directing that the Company's listing be transferred to the Nasdaq Capital Market, effective at the open of business on September 15, 2022, and the Company's common stock will continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan in full by no later than January 9, 2023. While the Company believes that it will be able to implement the Compliance Plan, there can be no assurance that the Company will be able to do so as prescribed, or at all. Failure to do so would result in the delisting of the Company's common stock from Nasdaq, which would likely have a material adverse effect on the trading and value of the Company's common stock.Board Change • Aug 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Dave Buckel was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 16Scopus BioPharma Provides Non-Compliance UpdateAs previously reported, on January 13, 2022, Scopus BioPharma Inc. (the Company") received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5500(b)(2) requiring listed securities to maintain a minimum Market Value of Listed Securities of $50,000,000. On July 13, 2022, the Company received an additional letter from Nasdaq stating that because the Company had not regained such compliance as of July 12, 2022, trading of the Company's common stock on Nasdaq would be suspended on July 22, 2022 and removed from listing and registration, unless the Company were to request an appeal to a Nasdaq hearings panel by July 20, 2022. The Company has been in contact with Nasdaq regarding the listing of its common stock and intends to pursue such an appeal. The Company believes that, until the hearings panel renders a decision on the Company's appeal, this delisting action would be stayed and the Company's common stock would continue to be listed on Nasdaq.お知らせ • May 21Scopus BioPharma Inc. Announces Resignation of Paul Hopper from Board of DirectorsScopus BioPharma Inc. announced that on May 18, 2022, Paul Hopper tendered a letter of resignation from the Board of Directors of the Company effective immediately.お知らせ • May 15Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022Scopus BioPharma Inc. announced resignation of Ashish Sanghrajka from the Board of Directors with effect from May 11, 2022.お知らせ • May 14Scopus BioPharma Inc. announced delayed 10-Q filingOn 05/13/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 06Scopus BioPharma Inc. Appoints Raphael Hofstein to its Board of DirectorsScopus BioPharma Inc. announced the appointment of Raphael (Rafi) Hofstein to its Board of Directors (Board). Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies. These companies include Fibrocor Therapeutics, a precision medicine company; BioLineRx; and Encycle Therapeutics. Dr. Hofstein is Chairman of Fibrocor, which has strategic partnerships with Evotec SE and Galapagos NV. Dr. Hofstein has been a director of BioLineRx since its inception. Encycle was acquired by Zealand Pharma A/S in 2019. Dr. Hofstein has also played key leadership roles in establishing industry partnerships and strategic alliances with leading global biopharmaceutical, biotechnology and pharmaceutical companies, including Amgen, Baxter, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer and Takeda. Dr. Hofstein fills a vacancy on the Board created by the voluntary resignations of directors who joined the Board as a result of the contested election relating to the 2021 Annual Meeting of Stockholders. The results of the contested election are being challenged in an action pursuant to Section 225 of Delaware’s General Corporation Law in the Delaware Court of Chancery.お知らせ • May 02Scopus Biopharma Inc. Announces Board ResignationsOn April 26, 2022, Joshua Levine and Mordechai Hacham each tendered a letter of resignation from the Board of Directors of Scopus BioPharma Inc., effective immediately.お知らせ • Apr 09Scopus BioPharma Receives Non-Compliance Letter from NasdaqOn April 4, 2022, Scopus BioPharma Inc. (the Company") received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from the date of such notice, or until October 3, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. Nasdaq's written notice has no effect on the listing or trading of the Company's common stock at this time, and the Company is currently evaluating its alternatives to resolve this listing deficiency.お知らせ • Apr 03Scopus BioPharma Inc. announced delayed annual 10-K filingOn 04/01/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 22Scopus BioPharma Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 13, 2022, Scopus BioPharma Inc. received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2) requiring listed securities to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 (the “MVLS Requirement”). The Company has 180 calendars days, expiring July 12, 2022, to regain compliance with the MVLS Requirement. If the Company maintains a MVLS at or greater than $50,000,000 for a minimum of ten consecutive business days, it will regain compliance. If the Company does not regain compliance within 180 calendar days, it will receive a written notification from Nasdaq that its securities are subject to delisting, and may have the opportunity to transfer its listing to The Nasdaq Capital Market (“Capital Market”) if it meets the Capital Market’s continued listing requirements and pays the applicable fee. The Company intends to monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the MVLS Requirement. There can be no assurance that the Company will be able to regain compliance with the MVLS Requirement or maintain compliance if the Company regains compliance.Executive Departure • Jul 14Independent Director Paul Hopper has left the companyOn the 2nd of July, Paul Hopper's tenure as Independent Director ended after 1.1 years in the role. We don't have any record of a personal shareholding under Paul's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.63 years.お知らせ • Jul 02Scopus BioPharma Inc. (NasdaqGM:SCPS) acquired Olimmune Inc.Scopus BioPharma Inc. (NasdaqGM:SCPS) entered into an agreement to acquire Olimmune Inc. for $14.3 million on June 25, 2021. The consideration paid Scopus issued to Olimmune stockholders 1,000,000 shares of common stock of the Company. We also issued 100,000 shares of common stock of the Company to COH as additional consideration for the two license agreements. Scopus BioPharma Inc. (NasdaqGM:SCPS) completed the acquisition of Olimmune Inc. on June 30, 2021.お知らせ • Jun 28+ 9 more updatesScopus BioPharma Inc.(NasdaqGM:SCPS) dropped from Russell Microcap Value IndexScopus BioPharma Inc.(NasdaqGM:SCPS) dropped from Russell Microcap Value Indexお知らせ • May 25Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug CandidateScopus BioPharma Inc. announced the approval of an investigational new drug application (“IND”) by the United States Food and Drug Administration (“FDA”) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope. Scopus is a biopharmaceutical company developing transformational therapeutics based on scientific and medical discoveries. City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases near Los Angeles, California. CpG-STAT3siRNA encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. This highly-distinctive drug candidate was developed in the City of Hope laboratories of Hua Yu, Ph.D. and Marcin Kortylewski, Ph.D. Yu is co-leader of the Cancer Immunotherapeutics Program and Billy and Audrey L. Wilder Professor in Tumor Immunotherapy. Kortylewski is a professor in the Department of Immuno-Oncology.お知らせ • Apr 27Scopus BioPharma Announces IND Submission to FDA for Lead Drug CandidateScopus BioPharma Inc. announced the submission of an investigational new drug application to the United States Food and Drug Administration for its immuno-oncology RNA therapy for the treatment of multiple cancers. The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to be initiated at City of Hope. The company's lead drug candidate encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. This highly-distinctive drug candidate was developed in the City of Hope laboratories of Hua Yu, Ph.D. and Marcin Kortylewski, Ph.D. Yu is co-leader of the Cancer Immunotherapeutics Program and Billy and Audrey L. Wilder Professor in Tumor Immunotherapy. Kortylewski is an associate professor in the Department of Immuno-Oncology.お知らせ • Mar 21Scopus Biopharma Inc. Announces Change of Board CommitteesScopus BioPharma Inc. announced that Dr. Raphael Hofstein became a member of the Audit Committee of the company, filling a vacancy created by the resignation of Dr. Lesley Russell, for reasons unrelated to the operations, policies, or practices of the company, accepted and/or ratified on March 15, 2021 and/or March 18, 2021, as the case may be. Dr. Hofstein assumes this position in addition to his role as a member of each of the Compensation Committee and Nominating Committee. In this connection, Dr. Hofstein also assumed the role of Chair of the Compensation Committee. Dr. Hofstein is considered to be an “independent director” under the rules of the Nasdaq Stock Market, which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company’s board of directors would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director.お知らせ • Mar 17Scopus BioPharma Inc. Finalizes Arrangements for Submission of IND PackageScopus BioPharma Inc. announced the finalization of arrangements for the completion of the investigational new drug ("IND") package for the company's lead drug candidate and its submission to the United States Food and Drug Administration ("FDA"). The IND submission is expected in second quarter of 2021. The company's lead drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.分析記事 • Mar 16Do Institutions Own Scopus BioPharma Inc. (NASDAQ:SCPS) Shares?The big shareholder groups in Scopus BioPharma Inc. ( NASDAQ:SCPS ) have power over the company. Insiders often own a...お知らせ • Jan 28Scopus BioPharma Inc. has completed a Follow-on Equity Offering in the amount of $9 million.Scopus BioPharma Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: $9お知らせ • Jan 20Scopus BioPharma Inc. Announces Completion of Clinical Lot Manufacturing Fulfilling the Requirements for the Planned Phase 1 Clinical Trial for Non-Hodgkin's LymphomaScopus BioPharma Inc. announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma. This is a key milestone to enable finalization of the investigational new drug ("IND") package for submission to the United States Food and Drug Administration ("FDA"). Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company's lead drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. An additional near-term milestone is a status report under the company's sponsored research agreement relating to its lead drug candidate in combination with checkpoint inhibitors.お知らせ • Dec 30Scopus BioPharma Inc Announces Appointment of Additional DirectorsScopus BioPharma Inc. announced the appointment of additional members to its Board of Directors. The new directors are: Raphael ("Rafi") Hofstein, Ph.D. Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies. Most recently, these companies include: Fibrocor Therapeutics; Encyte Therapeutics (acquired by Zealand Pharma A/S); and Notch Therapeutics, a biotechnology company focused on gene-edited T cell therapies, which has a strategic partnership with Allogene Therapeutics. Lesley Russell, MB.Ch.B, MRCP (UK). Dr. Russell has extensive leadership experience across diverse disciplines at numerous private and public biopharmaceutical, biotechnology and pharmaceutical companies. David S. Battleman, M.D. Dr. Battleman has extensive experience across academia; the biopharmaceutical, pharmaceutical and medical technology industries; and pharmaceutical and healthcare management consulting. David A. Buckel, CMA. Mr. Buckel has extensive experience as a senior executive officer, including chief financial officer and principal accounting officer, of numerous private and Nasdaq-listed public companies. Mr. Buckel is the President and Managing Director of BVI Venture Services, a provider of financial, accounting and management services to private and public companies. David Weild IV. Mr. Weild is a globally recognized leader in capital formation and capital markets structure. Mr. Weild authored and co-authored a number of definitive white papers that were key catalysts for new legislation and regulatory reforms, including the JOBS Act. Mr. Weild is Chairman and Chief Executive Officer of Weild & Co., a boutique investment bank focused on enhancing capital access for emerging growth companies. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Scopus BioPharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:SCPS - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2023N/A-9-3-3N/A3/31/2023N/A-9-5-5N/A12/31/2022N/A-12-8-8N/A9/30/2022N/A-16-12-12N/A6/30/2022N/A-16-14-14N/A3/31/2022N/A-28-13-13N/A12/31/2021N/A-27-11-11N/A9/30/2021N/A-21-8-8N/A6/30/2021N/A-21-6-6N/A3/31/2021N/A-14-5-5N/A12/31/2020N/A-11-3-3N/A9/30/2020N/A-11-2-2N/A6/30/2020N/A-10-2-2N/A3/31/2020N/A-3-2-2N/A12/31/2019N/A-3-2-2N/A9/30/2019N/A-2-2-2N/A6/30/2019N/A-1-1-1N/A3/31/2019N/A-1-1-1N/A12/31/2018N/A-1-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SCPSの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SCPSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SCPSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SCPSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SCPSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SCPSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 23:32終値2026/05/21 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Scopus BioPharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Aydin HuseynovBenchmark Company
お知らせ • Jan 20Scopus BioPharma Files Form 15Scopus BioPharma Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Nov 08Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant GliomaScopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski, Professor of Immuno-Oncology at City of Hope, is the Co-Founder and Senior Scientific Advisor of Duet. Duet is developing novel immunotherapies to overcome treatment-resistant cancers. DUET-102 is a double-stranded antisense oligonucleotide ("ASO") STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma. Glioma is a common type of tumor originating in the glial cells of the brain. Approximately 20,000 patients are diagnosed in the United States annually, with such patients having a 5-year survival rate of less than 7%, reflecting the need for new therapies to combat this disease. The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete injection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice. DUET-102 creates ideal conditions for PD-1 blockade to recruit cancer-killing effector CD8 positive T cells into the tumor by activating intratumoral dendritic cells, M1 macrophages, and microglia, while concurrently reducing immunosuppressive tumor-associated M2 macrophages, resting microglia, and regulatory T cells. DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma. DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs. Furthermore, the effectiveness of DUET-102 in releasing immunosuppression may enhance the efficacy of other T-cell based immunotherapies in the context of glioma, including potential combinations of DUET-102 with adoptive cell transfer therapies, such as CAR T-cell therapies.
お知らせ • Dec 17Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price RequirementAs previously disclosed, Scopus BioPharma Inc. has not satisfied certain requirements for continued listing of the Nasdaq Stock Market LLC (“Nasdaq”), including: (i) the minimum Market Value of Listed Securities; (ii) the minimum Market Value of Publicly Held Shares; and (iii) the minimum closing bid price. As also previously disclosed, the Company had a hearing, on August 25, 2022, with the Nasdaq Hearings Panel (the “Panel”) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the “Compliance Plan”). By letter dated September 13, 2022, Nasdaq informed the Company of the Panel’s decision directing that the Company’s listing be transferred to the Nasdaq Capital Market and that the Company’s common stock would continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan. As reported on December 2, 2022, the Company failed to comply with, among other things, milestone dates included in the Compliance Plan. In response to the Company informing the Panel of an inability to complete a specified financing transaction by a subsequent milestone date, the Panel informed the Company, by letter dated December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol SCPS". The Company has submitted an application for trading of its common stock on the OTCQB Venture Market (the OTCQB"). The OTCQB requires, among other things, that companies be current with and otherwise satisfy applicable reporting requirements. The Company intends to continue to comply with applicable reporting requirements under the Securities Exchange Act of 1934. There can be no assurance that the Company's application to trade on the OTCQB will be approved on a timely basis or at all or that the Company will be able to satisfy reporting and other applicable requirements.
お知らせ • Dec 05Scopus BioPharma Inc. Announces Update on Deficiency Notification Letters from Nasdaq Regarding Minimum Bid Price RequirementAs previously reported, Scopus BioPharma Inc. (the ‘company’) received deficiency notification letters from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (‘Nasdaq’ or the ‘Exchange’) indicating that the Company was not in compliance with Nasdaq’s ‘minimum bid price’ requirement, which requires that the bid price of the stock of listed companies be at least $1.00 per share (the ‘Minimum Bid Price Requirement’) and certain Nasdaq listing rules relating to maintaining a minimum market value of listed securities of $50,000,000 (the ‘MVLS Requirement’) and a minimum market value of publicly held shares of $15,000,000 (the ‘MVPHS Requirement’ and, together with the Minimum Bid Price Requirement and the MVLS Requirement, the ‘Listing Requirements’). Also, as previously disclosed, the Company participated in a hearing on August 25, 2022 with the Nasdaq Hearings Panel (the ‘Panel’) at which the Panel considered the Company’s plan for regaining compliance with Nasdaq listing standards (the ‘Compliance Plan’). Also, as previously disclosed, on September 13, 2022, Nasdaq informed the Company of the Panel’s decision (the ‘Decision’) directing that the Company’s listing be transferred to the Nasdaq Capital Market, effective at the open of business on September 15, 2022, and the Company’s common stock will continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan in full by no later than January 9, 2023. The Company failed to comply with milestone dates set forth in the Compliance Plan and did not timely inform Nasdaq of such failure. By letter dated December 1, 2022, Nasdaq informed the Company that the Panel has determined to grant the Company a final extension to such milestone dates and publicly reprimanded the Company. Such public reprimand, pursuant to Listing Rule 5815(c)(1)(D), was issued to the Company for its failure to comply with Listing Rule 5250(a)(1), requiring it to notify Nasdaq of certain significant developments that led to its prior representations about its ability to satisfy the terms of the Decision and, therefore, the Exchange’s continued listing requirements being inaccurate. While the Company is continuing to use its best efforts to satisfy the Listing Requirements in full by no later than January 9, 2023, there can be no assurance that the Company will be able to do so as set forth in the Compliance Plan, as amended, or at all. Failure to do so would result in the delisting of the Company’s common stock from Nasdaq, which would likely have a material adverse effect on the trading and value of the Company’s common stock.
お知らせ • Nov 16Scopus BioPharma Inc. announced delayed 10-Q filingOn 11/15/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Dave Buckel was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 10Scopus Biopharma Receives Additional Non-Compliance Letter from NasdaqScopus BioPharma Inc. announced that on October 4, 2022, the company received additional letter from Nasdaq as the company had not regained compliance with minimum bid price standard as of October 3, 2022.
お知らせ • Sep 17Scopus BioPharma Provides Delisting UpdateAs previously disclosed on a Form 8-K filed on September 2, 2022, Scopus BioPharma Inc., on August 25, 2022, presented its plan (the Compliance Plan") for regaining compliance with continued listing standards of the Nasdaq Stock Market LLC (Nasdaq") to the Nasdaq Hearings Panel (the Panel"). By letter dated September 13, 2022, Nasdaq informed the Company of the Panel's decision directing that the Company's listing be transferred to the Nasdaq Capital Market, effective at the open of business on September 15, 2022, and the Company's common stock will continue to be listed on that market subject to, among other things, the Company satisfying the Compliance Plan in full by no later than January 9, 2023. While the Company believes that it will be able to implement the Compliance Plan, there can be no assurance that the Company will be able to do so as prescribed, or at all. Failure to do so would result in the delisting of the Company's common stock from Nasdaq, which would likely have a material adverse effect on the trading and value of the Company's common stock.
Board Change • Aug 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Dave Buckel was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 16Scopus BioPharma Provides Non-Compliance UpdateAs previously reported, on January 13, 2022, Scopus BioPharma Inc. (the Company") received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5500(b)(2) requiring listed securities to maintain a minimum Market Value of Listed Securities of $50,000,000. On July 13, 2022, the Company received an additional letter from Nasdaq stating that because the Company had not regained such compliance as of July 12, 2022, trading of the Company's common stock on Nasdaq would be suspended on July 22, 2022 and removed from listing and registration, unless the Company were to request an appeal to a Nasdaq hearings panel by July 20, 2022. The Company has been in contact with Nasdaq regarding the listing of its common stock and intends to pursue such an appeal. The Company believes that, until the hearings panel renders a decision on the Company's appeal, this delisting action would be stayed and the Company's common stock would continue to be listed on Nasdaq.
お知らせ • May 21Scopus BioPharma Inc. Announces Resignation of Paul Hopper from Board of DirectorsScopus BioPharma Inc. announced that on May 18, 2022, Paul Hopper tendered a letter of resignation from the Board of Directors of the Company effective immediately.
お知らせ • May 15Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022Scopus BioPharma Inc. announced resignation of Ashish Sanghrajka from the Board of Directors with effect from May 11, 2022.
お知らせ • May 14Scopus BioPharma Inc. announced delayed 10-Q filingOn 05/13/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 06Scopus BioPharma Inc. Appoints Raphael Hofstein to its Board of DirectorsScopus BioPharma Inc. announced the appointment of Raphael (Rafi) Hofstein to its Board of Directors (Board). Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies. These companies include Fibrocor Therapeutics, a precision medicine company; BioLineRx; and Encycle Therapeutics. Dr. Hofstein is Chairman of Fibrocor, which has strategic partnerships with Evotec SE and Galapagos NV. Dr. Hofstein has been a director of BioLineRx since its inception. Encycle was acquired by Zealand Pharma A/S in 2019. Dr. Hofstein has also played key leadership roles in establishing industry partnerships and strategic alliances with leading global biopharmaceutical, biotechnology and pharmaceutical companies, including Amgen, Baxter, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer and Takeda. Dr. Hofstein fills a vacancy on the Board created by the voluntary resignations of directors who joined the Board as a result of the contested election relating to the 2021 Annual Meeting of Stockholders. The results of the contested election are being challenged in an action pursuant to Section 225 of Delaware’s General Corporation Law in the Delaware Court of Chancery.
お知らせ • May 02Scopus Biopharma Inc. Announces Board ResignationsOn April 26, 2022, Joshua Levine and Mordechai Hacham each tendered a letter of resignation from the Board of Directors of Scopus BioPharma Inc., effective immediately.
お知らせ • Apr 09Scopus BioPharma Receives Non-Compliance Letter from NasdaqOn April 4, 2022, Scopus BioPharma Inc. (the Company") received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from the date of such notice, or until October 3, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. Nasdaq's written notice has no effect on the listing or trading of the Company's common stock at this time, and the Company is currently evaluating its alternatives to resolve this listing deficiency.
お知らせ • Apr 03Scopus BioPharma Inc. announced delayed annual 10-K filingOn 04/01/2022, Scopus BioPharma Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 22Scopus BioPharma Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 13, 2022, Scopus BioPharma Inc. received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2) requiring listed securities to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 (the “MVLS Requirement”). The Company has 180 calendars days, expiring July 12, 2022, to regain compliance with the MVLS Requirement. If the Company maintains a MVLS at or greater than $50,000,000 for a minimum of ten consecutive business days, it will regain compliance. If the Company does not regain compliance within 180 calendar days, it will receive a written notification from Nasdaq that its securities are subject to delisting, and may have the opportunity to transfer its listing to The Nasdaq Capital Market (“Capital Market”) if it meets the Capital Market’s continued listing requirements and pays the applicable fee. The Company intends to monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the MVLS Requirement. There can be no assurance that the Company will be able to regain compliance with the MVLS Requirement or maintain compliance if the Company regains compliance.
Executive Departure • Jul 14Independent Director Paul Hopper has left the companyOn the 2nd of July, Paul Hopper's tenure as Independent Director ended after 1.1 years in the role. We don't have any record of a personal shareholding under Paul's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.63 years.
お知らせ • Jul 02Scopus BioPharma Inc. (NasdaqGM:SCPS) acquired Olimmune Inc.Scopus BioPharma Inc. (NasdaqGM:SCPS) entered into an agreement to acquire Olimmune Inc. for $14.3 million on June 25, 2021. The consideration paid Scopus issued to Olimmune stockholders 1,000,000 shares of common stock of the Company. We also issued 100,000 shares of common stock of the Company to COH as additional consideration for the two license agreements. Scopus BioPharma Inc. (NasdaqGM:SCPS) completed the acquisition of Olimmune Inc. on June 30, 2021.
お知らせ • Jun 28+ 9 more updatesScopus BioPharma Inc.(NasdaqGM:SCPS) dropped from Russell Microcap Value IndexScopus BioPharma Inc.(NasdaqGM:SCPS) dropped from Russell Microcap Value Index
お知らせ • May 25Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug CandidateScopus BioPharma Inc. announced the approval of an investigational new drug application (“IND”) by the United States Food and Drug Administration (“FDA”) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope. Scopus is a biopharmaceutical company developing transformational therapeutics based on scientific and medical discoveries. City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases near Los Angeles, California. CpG-STAT3siRNA encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. This highly-distinctive drug candidate was developed in the City of Hope laboratories of Hua Yu, Ph.D. and Marcin Kortylewski, Ph.D. Yu is co-leader of the Cancer Immunotherapeutics Program and Billy and Audrey L. Wilder Professor in Tumor Immunotherapy. Kortylewski is a professor in the Department of Immuno-Oncology.
お知らせ • Apr 27Scopus BioPharma Announces IND Submission to FDA for Lead Drug CandidateScopus BioPharma Inc. announced the submission of an investigational new drug application to the United States Food and Drug Administration for its immuno-oncology RNA therapy for the treatment of multiple cancers. The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to be initiated at City of Hope. The company's lead drug candidate encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. This highly-distinctive drug candidate was developed in the City of Hope laboratories of Hua Yu, Ph.D. and Marcin Kortylewski, Ph.D. Yu is co-leader of the Cancer Immunotherapeutics Program and Billy and Audrey L. Wilder Professor in Tumor Immunotherapy. Kortylewski is an associate professor in the Department of Immuno-Oncology.
お知らせ • Mar 21Scopus Biopharma Inc. Announces Change of Board CommitteesScopus BioPharma Inc. announced that Dr. Raphael Hofstein became a member of the Audit Committee of the company, filling a vacancy created by the resignation of Dr. Lesley Russell, for reasons unrelated to the operations, policies, or practices of the company, accepted and/or ratified on March 15, 2021 and/or March 18, 2021, as the case may be. Dr. Hofstein assumes this position in addition to his role as a member of each of the Compensation Committee and Nominating Committee. In this connection, Dr. Hofstein also assumed the role of Chair of the Compensation Committee. Dr. Hofstein is considered to be an “independent director” under the rules of the Nasdaq Stock Market, which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company’s board of directors would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director.
お知らせ • Mar 17Scopus BioPharma Inc. Finalizes Arrangements for Submission of IND PackageScopus BioPharma Inc. announced the finalization of arrangements for the completion of the investigational new drug ("IND") package for the company's lead drug candidate and its submission to the United States Food and Drug Administration ("FDA"). The IND submission is expected in second quarter of 2021. The company's lead drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
分析記事 • Mar 16Do Institutions Own Scopus BioPharma Inc. (NASDAQ:SCPS) Shares?The big shareholder groups in Scopus BioPharma Inc. ( NASDAQ:SCPS ) have power over the company. Insiders often own a...
お知らせ • Jan 28Scopus BioPharma Inc. has completed a Follow-on Equity Offering in the amount of $9 million.Scopus BioPharma Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: $9
お知らせ • Jan 20Scopus BioPharma Inc. Announces Completion of Clinical Lot Manufacturing Fulfilling the Requirements for the Planned Phase 1 Clinical Trial for Non-Hodgkin's LymphomaScopus BioPharma Inc. announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma. This is a key milestone to enable finalization of the investigational new drug ("IND") package for submission to the United States Food and Drug Administration ("FDA"). Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company's lead drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. An additional near-term milestone is a status report under the company's sponsored research agreement relating to its lead drug candidate in combination with checkpoint inhibitors.
お知らせ • Dec 30Scopus BioPharma Inc Announces Appointment of Additional DirectorsScopus BioPharma Inc. announced the appointment of additional members to its Board of Directors. The new directors are: Raphael ("Rafi") Hofstein, Ph.D. Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies. Most recently, these companies include: Fibrocor Therapeutics; Encyte Therapeutics (acquired by Zealand Pharma A/S); and Notch Therapeutics, a biotechnology company focused on gene-edited T cell therapies, which has a strategic partnership with Allogene Therapeutics. Lesley Russell, MB.Ch.B, MRCP (UK). Dr. Russell has extensive leadership experience across diverse disciplines at numerous private and public biopharmaceutical, biotechnology and pharmaceutical companies. David S. Battleman, M.D. Dr. Battleman has extensive experience across academia; the biopharmaceutical, pharmaceutical and medical technology industries; and pharmaceutical and healthcare management consulting. David A. Buckel, CMA. Mr. Buckel has extensive experience as a senior executive officer, including chief financial officer and principal accounting officer, of numerous private and Nasdaq-listed public companies. Mr. Buckel is the President and Managing Director of BVI Venture Services, a provider of financial, accounting and management services to private and public companies. David Weild IV. Mr. Weild is a globally recognized leader in capital formation and capital markets structure. Mr. Weild authored and co-authored a number of definitive white papers that were key catalysts for new legislation and regulatory reforms, including the JOBS Act. Mr. Weild is Chairman and Chief Executive Officer of Weild & Co., a boutique investment bank focused on enhancing capital access for emerging growth companies.